Back to results
US 2006/0135611 A1Published application
Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function
OwnerJose Esteve-Soler, Inigo Saenz De Tejada-Gorman +1inventors
InventorsJose Esteve-Soler, Inigo Saenz De Tejada-Gorman, Javier Angulo-Frutos
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of 2,5-dihydroxybenzenesulfonic compounds for the manufacture of a medicament for the regulation of nitric oxide (NO) synthesis and/or the regulation of EDHF (Endothelium-Derived-Hyperpolarizing-Factor) in the endothelium of diabetic patients, whereby the medicament is administered in a daily dose of the 2,5-dihydroxybenzenesulfonic compounds of formula (I) of <500 mg.
Claims25
Use of at least one of the 2,5-dihydroxybenzenesulfonic compounds of general formula I,
- wherein
- R represents H or SO3-,
- B represents at least one cation
- n represents 1 or 2
- m represents 1 or 2,
- optionally in form of a pharmaceutically acceptable solvate, for the manufacture of a medicament for the regulation of nitric oxide (NO) synthesis and/or the regulation of EDHF (Endothelium-Derived-Hyperpolarizing-Factor) in the endothelium of diabetic patients, whereby the medicament is administered in a daily dose of the afore mentioned compounds of formula I of <500 mg.
3 more elements
Dependencies are inferred from the claim text.